Energiekontor AG

  • WKN: 531350
  • ISIN: DE0005313506
  • Land: Deutschland

Nachricht vom 04.10.2021 | 07:30

Energiekontor AG: Release of a capital market information

Energiekontor AG / Announcement pursuant to Article 5 (1b) and (3) of Regulation (EU) No. 596/2014 and Art. 2 (2) and (3) of Commission Delegated Regulation (EU) No. 2016/1052
04.10.2021 / 07:30
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Interim report #19

In the period from 27 September 2021 to 1 October 2021, Energiekontor AG acquired a total of 3,500 shares within the framework of the share buyback announced on 21 May 2021 pursuant to Art. 2 Par. 1 of the delegated Regulation (EU) 2016/1052.

The total number of shares repurchased, the weighted average price and the aggregated volume were as follows for each day of the period mentioned:

Date Total number of shares repurchased (units) Weighted average price (Euro) Aggregate volume (Euro)
10/01/2021 400 59.9500 23,980.00
09/30/2021 550 60.8509 33,468.00
09/29/2021 700 60.2814 42,196.98
09/28/2021 1,150 59.1956 68,074.96
09/27/2021 700 59.6429 41,750.00
 

The total number of shares bought back under the share buyback programme since 25 May 2021 is 78,823.

The acquisition of the shares of Energiekontor AG was carried out by a credit institution commissioned by Energiekontor AG exclusively via the Frankfurt Stock Exchange (XETRA trading).

Further information on the individual transactions of the share buyback pursuant to Art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) No. 596/2014 in conjunction with Art. 2 para. 1, para. 2 and para. 3 of the Delegate Regulation (EU) No. 2016/1052 is available on the Internet at www.energiekontor.de/en/investor-relations/share-buyback

Bremen, 4 October 2021

Energiekontor AG

The Management Board



04.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021